Hormonal therapy for preeclampsia - Adepthera
Latest Information Update: 15 Aug 2016
At a glance
- Originator Adepthera
- Mechanism of Action G protein-coupled receptor agonists; Signal transducing adaptor protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Preeclampsia; Preterm labour
Most Recent Events
- 12 Aug 2016 Preclinical trials in Preeclampsia in USA (unspecified route)
- 12 Aug 2016 Preclinical trials in Preterm labour (Prevention) in USA (unspecified route)